Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill, approved by U.S. authorities on Friday, that caters for patients with an aversion to needles. Reuters Health News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Time limit is exhausted. Please reload CAPTCHA.